Madeleine E. Cunningham

Madeleine E. Cunningham

Auto-generated profile, based on publicly available information

Madeleine E. Cunningham

Neuroimmunology Group, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2016 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
RMRhona McGonigal
Rhona McGonigal
MCMadeleine E. Cunningham
Madeleine E. Cunningham
DYDenggao Yao
Denggao Yao
JBJennifer A. Barrie
Jennifer A. Barrie
SSSethu Sankaranarayanan
Sethu Sankaranarayanan
HWHugh J. Willison
Hugh J. Willison
Guillain-Barré syndrome (GBS) is an autoimmune disease that results in acute paralysis through inflammatory attack on peripheral nerves, and currently has limited, non-specific treatment options. The pathogenesis of the acute motor axonal neuropathy (AMAN) variant is mediated by complement-fixing anti-ganglioside antibodies that directly bind and injure the axon at sites of vulnerability such as nodes of Ranvier and nerve terminals. Consequently, the complement cascade is an attractive target to reduce disease severity. Recently, C5 complement component inhibitors that block the formation of the membrane attack complex and subsequent downstream injury have been shown to be efficacious in an in vivo anti-GQ1b antibody-mediated mouse model of the GBS variant Miller Fisher syndrome (MFS). However, since gangliosides are widely expressed in neurons and glial cells, injury in this model was not targeted exclusively to the axon and there are currently no pure mouse models for AMAN. Additionally, C5 inhibition does not prevent the production of early complement fragments such as C3a and C3b that can be deleterious via their known role in immune cell and macrophage recruitment to sites of neuronal damage. In this study, we first developed a new in vivo transgenic mouse model of AMAN using mice that express complex gangliosides exclusively in neurons, thereby enabling specific targeting of axons with anti-ganglioside antibodies. Secondly, we have evaluated the efficacy of a novel anti-C1q antibody (M1) that blocks initiation of the classical complement cascade, in both the newly developed anti-GM1 antibody-mediated AMAN model and our established MFS model in vivo. Anti-C1q monoclonal antibody treatment attenuated complement cascade activation and deposition, reduced immune cell recruitment and axonal injury, in both mouse models of GBS, along with improvement in respiratory function. These results demonstrate that neutralising C1q function attenuates injury with a consequent neuroprotective effect in acute GBS models and promises to be a useful new target for human therapy.

23 June 2017 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
SCStephanie L. Cumberworth
Stephanie L. Cumberworth
JBJennifer A. Barrie
Jennifer A. Barrie
MCMadeleine E. Cunningham
Madeleine E. Cunningham
DFDaniely Paulino Gomes de Figueiredo
Daniely Paulino Gomes de Figueiredo
VSVerena Schultz
Verena Schultz
JEJulia Edgar
Julia Edgar
The recent global outbreak of Zika virus (ZIKV) infection has been linked to severe neurological disorders affecting the peripheral and central nervous systems (PNS and CNS, respectively). The pathobiology underlying these diverse clinical phenotypes are the subject of intense research; however, even the principal neural cell types vulnerable to productive Zika infection remain poorly characterised. Here we used CNS and PNS myelinating cultures from wild type and Ifnar1 knockout mice to examine neuronal and glial tropism and short-term consequences of direct infection with a Brazilian variant of ZIKV. Cell cultures were infected pre- or post-myelination for various intervals, then stained with cell-type and ZIKV-specific antibodies. In bypassing systemic immunity using ex vivo culture, and the type I interferon response in Ifnar1 deficient cells, we were able to evaluate the intrinsic infectivity of neural cells. Through systematic quantification of ZIKV infected cells in myelinating cultures, we found that ZIKV infection is enhanced in the absence of the type I interferon responses and that CNS cells are considerably more susceptible to infection than PNS cells. In particular, we demonstrate that CNS axons and myelinating oligodendrocytes are especially vulnerable to injury. These results have implications for understanding the pathobiology of neurological symptoms associated with ZIKV infection. Furthermore, we provide a quantifiable ex vivo infection model that can be used for fundamental and therapeutic studies on viral neuroinvasion and its consequences.

15 January 2014 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
DYDenggao Yao
Denggao Yao
RMRhona McGonigal
Rhona McGonigal
JBJennifer A. Barrie
Jennifer A. Barrie
JCJoanna Cappell
Joanna Cappell
MCMadeleine E. Cunningham
Madeleine E. Cunningham
HWHugh Willison
Hugh Willison
Gangliosides are widely expressed sialylated glycosphingolipids with multifunctional properties in different cell types and organs. In the nervous system, they are highly enriched in both glial and neuronal membranes. Mice lacking complex gangliosides attributable to targeted ablation of the B4galnt1 gene that encodes β-1,4-N-acetylegalactosaminyltransferase 1 (GalNAc–transferase;GalNAcT−/−) develop normally before exhibiting an age-dependent neurodegenerative phenotype characterized by marked behavioral abnormalities, central and peripheral axonal degeneration, reduced myelin volume, and loss of axo-glial junction integrity. The cell biological substrates underlying this neurodegeneration and the relative contribution of either glial or neuronal gangliosides to the process are unknown. To address this, we generated neuron-specific and glial-specific GalNAcT rescue mice crossed on the globalGalNAcT−/−background [GalNAcT−/−-Tg(neuronal) andGalNAcT−/−-Tg(glial)] and analyzed their behavioral, morphological, and electrophysiological phenotype. Complex gangliosides, as assessed by thin-layer chromatography, mass spectrometry, GalNAcT enzyme activity, and anti-ganglioside antibody (AgAb) immunohistology, were restored in both neuronal and glial GalNAcT rescue mice. Behaviorally,GalNAcT−/−-Tg(neuronal) retained a normal “wild-type” (WT) phenotype throughout life, whereasGalNAcT−/−-Tg(glial) resembledGalNAcT−/−mice, exhibiting progressive tremor, weakness, and ataxia with aging. Quantitative electron microscopy demonstrated thatGalNAcT−/−andGalNAcT−/−-Tg(glial)nerves had significantly increased rates of axon degeneration and reduced myelin volume, whereasGalNAcT−/−-Tg(neuronal)and WT appeared normal. The increased invasion of the paranode with juxtaparanodal Kv1.1, characteristically seen inGalNAcT−/−and attributed to a breakdown of the axo-glial junction, was normalized inGalNAcT−/−-Tg(neuronal)but remained present inGalNAcT−/−-Tg(glial)mice. These results indicate that neuronal rather than glial gangliosides are critical to the age-related maintenance of nervous system integrity.

16 November 2018 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
RMRhona McGonigal
Rhona McGonigal
JBJennifer A. Barrie
Jennifer A. Barrie
DYDenggao Yao
Denggao Yao
MMMark McLaughlin
Mark McLaughlin
MCMadeleine E. Cunningham
Madeleine E. Cunningham
HWHugh Willison
Hugh Willison
Sulfatides and gangliosides are raft-associated glycolipids essential for maintaining myelinated nerve integrity. Mice deficient in sulfatide (cerebroside sulfotransferase knock-out,CST−/−) or complex gangliosides (β-1,4-N-acetylegalactosaminyltransferase1 knock-out,GalNAc-T−/−) display prominent disorganization of proteins at the node of Ranvier (NoR) in early life and age-dependent neurodegeneration. Loss of neuronal rather than glial complex gangliosides underpins theGalNAc-T−/−phenotype, as shown by neuron- or glial-specific rescue, whereas sulfatide is principally expressed and functional in glial membranes. The similarities in NoR phenotype ofCST−/−,GalNAc-T−/−, and axo–glial protein-deficient mice suggests that these glycolipids stabilize membrane proteins including neurofascin155 (NF155) and myelin-associated glycoprotein (MAG) at axo–glial junctions. To assess the functional interactions between sulfatide and gangliosides,CST−/−andGalNAc-T−/−genotypes were interbred.CST−/−×GalNAc-T−/−mice develop normally to postnatal day 10 (P10), but all die between P20 and P25, coinciding with peak myelination. Ultrastructural, immunohistological, and biochemical analysis of either sex revealed widespread axonal degeneration and disruption to the axo–glial junction at the NoR. In addition to sulfatide-dependent loss of NF155,CST−/−×GalNAc-T−/−mice exhibited a major reduction in MAG protein levels in CNS myelin compared with WT and single-lipid-deficient mice. TheCST−/−×GalNAc-T−/−phenotype was fully restored to that ofCST−/−mice by neuron-specific expression of complex gangliosides, but not by their glial-specific expression nor by the global expression ofa-series gangliosides. These data indicate that sulfatide and complexb-series gangliosides on the glial and neuronal membranes, respectively, act in concert to promote NF155 and MAG in maintaining the stable axo–glial interactions essential for normal nerve function.SIGNIFICANCE STATEMENTSulfatides and complex gangliosides are membrane glycolipids with important roles in maintaining nervous system integrity. Node of Ranvier maintenance in particular requires stable compartmentalization of multiple membrane proteins. The axo–glial adhesion molecules neurofascin155 (NF155) and myelin-associated glycoprotein (MAG) require membrane microdomains containing either sulfatides or complex gangliosides to localize and function effectively. The cooperative roles of these microdomains and associated proteins are unknown. Here, we show vital interdependent roles for sulfatides and complex gangliosides because double (but not single) deficiency causes a rapidly lethal phenotype at an early age. These findings suggest that sulfatides and complex gangliosides on opposing axo–glial membranes are responsible for essential tethering of the axo–glial junction proteins NF155 and MAG, which interact to maintain the nodal complex.

6 April 2020 in Journal of the Peripheral Nervous System
Verified
Journal Article
Open access
PDF file
MCMadeleine E. Cunningham
Madeleine E. Cunningham
GMGavin R. Meehan
Gavin R. Meehan
SRSophie Robinson
Sophie Robinson
DYDenggao Yao
Denggao Yao
RMRhona McGonigal
Rhona McGonigal
HWHugh Willison
Hugh Willison
Background and Aims In mouse models of acute motor axonal neuropathy (AMAN), anti‐ganglioside antibodies bind to motor axons, notably the distal nerve, and activate the complement cascade. Whilst complement activation is well studied in this model, the role of inflammatory cells is unknown. Herein we aimed to investigate the contribution of phagocytic cells including macrophages, neutrophils and perisynaptic Schwann cells (pSCs) to distal nerve pathology. To observe this, we first created a subacute injury model of sufficient duration to allow inflammatory cell recruitment. Methods Mice were injected intraperitoneally with an anti‐GD1b monoclonal antibody that binds strongly to mouse motor nerve axons. Subsequently, mice received normal human serum (NHS) as a source of complement. Dosing was titrated to allow humane survival of mice over a period of 3 days, yet still induce the characteristic neurological impairment. Behaviour and pathology were assessed in vivo using whole body plethysmography and post‐sacrifice by immunofluorescence and flow cytometry. Ex vivo nerve‐muscle preparations were used to investigate the acute phagocytic role of pSCs following distal nerve injury. Results Following complement activation at distal intramuscular nerve sites in the diaphragm macrophage localisation or numbers are not altered, nor do they shift to a pro‐ or anti‐inflammatory phenotype. Similarly, neutrophils are not significantly recruited. Instead, ex vivo nerve‐muscle preparations exposed to anti‐ganglioside antibody plus complement reveal that pSCs rapidly become phagocytic and engulf axonal debris. Interpretation These data suggest that pSCs, rather than inflammatory cells, are the major cellular vehicle for axonal debris clearance following distal nerve injury, in contrast to larger nerve bundles where macrophage‐mediated clearance predominates.

15 July 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RMRhona McGonigal
Rhona McGonigal
CCClare I. Campbell
Clare I. Campbell
JBJennifer A. Barrie
Jennifer A. Barrie
DYDenggao Yao
Denggao Yao
MCMadeleine E. Cunningham
Madeleine E. Cunningham
HWHugh Willison
Hugh Willison
In Guillain-Barré syndrome (GBS), both axonal and demyelinating variants can be mediated by complement-fixing anti–GM1 ganglioside autoantibodies that target peripheral nerve axonal and Schwann cell (SC) membranes, respectively. Critically, the extent of axonal degeneration in both variants dictates long-term outcome. The differing pathomechanisms underlying direct axonal injury and the secondary bystander axonal degeneration following SC injury are unresolved. To investigate this, we generated glycosyltransferase-disrupted transgenic mice that express GM1 ganglioside either exclusively in neurons [GalNAcT–/–-Tg(neuronal)] or glia [GalNAcT–/–-Tg(glial)], thereby allowing anti-GM1 antibodies to solely target GM1 in either axonal or SC membranes, respectively. Myelinated-axon integrity in distal motor nerves was studied in transgenic mice exposed to anti-GM1 antibody and complement in ex vivo and in vivo injury paradigms. Axonal targeting induced catastrophic acute axonal disruption, as expected. When mice with GM1 in SC membranes were targeted, acute disruption of perisynaptic glia and SC membranes at nodes of Ranvier (NoRs) occurred. Following glial injury, axonal disruption at NoRs also developed subacutely, progressing to secondary axonal degeneration. These models differentiate the distinctly different axonopathic pathways under axonal and glial membrane targeting conditions, and provide insights into primary and secondary axonal injury, currently a major unsolved area in GBS research.